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Introduction
Despite the recent progress in treatment of infectious diseases caused by Mycobacterium spp., these microorganisms continue to represent a considerable problem in world health control. Over 2 billion people are infected by Mycobacteria (mostly M. tuberculosis) and each tenth of them suffers from apparent form of these infections (e.g. tuberculosis) [1] . Distribution of mycobacterial infections in the world's population steadily increases, mainly due to the raising human mobility as well as the raising resistance of particular strains. Nowadays, the tuberculosis strains become multi drug resistant (MDR-TB), extensively drug resistant (XDR-TB), and very recently also totally drug resistant (TDR-TB). Moreover, some species of Mycobacteria such as M. avium do not have any universally efficient treatment protocol [2] . The increasing strains resistance, especially the crossresistance, led to the current extensive explorations and studies on new antituberculotics featuring improved or different mechanism of action [3] .
Five-membered heterocycles (azoles) such as pyrroles [4] , isoxazoles [5] , oxadiazoles [6] , and imidazoles [7] constitute one of the structural motives used for the design of therapeutic agents to date. Di(tri) azole derivatives found wide applications as antifungal agents (e.g. flukonazole, itraconazole, clotrimazole) . Imidazole-derived antibiotic agents belong to a large sub-class of the aforementioned drugs, from which metronidazole and its derivatives are certainly the most widely applied antibiotics against anaerobic bacteria and protozoa ( Fig. 1) [8] . 2-(Hetero)arylazole linkage was recently recognized as efficient structural arrangement in pyrrole, oxazole, and oxadiazole derivatives that feature respectable antimycobacterial activities (Fig. 1 ) [4] [5] [6] .
Recently, we have screened the antimycobacterial activities of various 2-phenylimidazoline [9] as well as benzimidazole, benzthiazole, and benzoxazole derivatives [10] . This screening revealed very promising activities of compounds 1-2 (Fig. 1) . In general, these derivatives possess the following important structural features: -i) central azole derivative, ii) 2-(hetero)aryl linkage, and iii) carbamate moiety known as active functional group of many AChE inhibitors [11] . Inspired by the success of these particular structural features, we have proposed to investigate N-Cbz α-amino acidderived 2-phenylimidazoles 5 (Fig. 1) . These derivatives, which were originally intended as optically active nitrogen ligands for asymmetric catalysis [12] , combine all of the aforementioned structural features into one molecule. According to our previous studies on the terminal nitro group effect on the antimycobacterial activity [10] , the series of compounds 5a-g was further completed with nitro analogs 6a-g.
Experimental procedure

General
Reagent and solvents were reagent-grade or HPLCgrade and were purchased from Penta, Aldrich and Acros and used as received. Tetrahydrofuran (THF) was distilled from sodium benzophenone ketyl radical. N-Cbz protected α-amino acids [13] , α-diazoketones 3a-g, α-bromoketones 4a-g, and imidazole derivatives 5a-g were synthesized according to the literature procedure and their analytical data were in accordance with those previously published [12a].
Synthesis
Preparation of 4-nitrobenzamidine hydrochloride (modification of [14])
Sodium methoxide (0.165 g; 3.1 mmol) was added to a solution of 4-nitrobenzonitrile (4.8 g, 32.4 mmol) in dry methanol (15 mL) and the reaction was refluxed for 12 h (monitored by TLC and GC/MS). Ammonium chloride (2.85 g, 53.3 mmol) was added and the reaction mixture was allowed to cool to 25°C. The resulting yellow suspension was filtered off and the filtration cake was washed with dry methanol and diethylether to afford the title compound as a yellow solid. Yield 3.85 g (59%). 
Preparation of 2-phenylimidazoles 6a-g -general procedure (modification of [12a])
A solution of α-bromoketone 4a-g (29.0 mmol) in THF (50 mL) was added dropwise into a refluxing solution of 4-nitrobenzamidine hydrochloride (5.85 g; 29.0 mmol) and anhydrous sodium carbonate (12.3 g, 116.0 mmol) in THF (80 mL) and water (20 mL) and the reaction mixture was further refluxed for the indicated time (Table 1 , monitored by TLC). The crude reaction mixture was concentrated in vacuo and the residue was portioned between dichloromethane (40 mL) and water (40 mL), the layers were separated, and the water layer was extracted with dichloromethane (2 × 60 mL). Combined organic layers were washed with water (100 mL), brine (100 mL), dried (Na 2 SO 4 ), and the solvent was evaporated in vacuo. The crude product was purified by column chromatography (SiO 2 ; EtOAc/ hexane 1:1).
2-(4-Nitrophenyl)-4-(1-(S)-benzyloxycarbonylaminoethyl)-1H-imidazole (6a)
The title compound was synthesized from α-bromoketone 4a (8.7 g, 29.0 mmol) following the general method. Yellowish solid, yield 2.7 g (25% 45.1, 65.3, 124.3, 125.4, 127.8, 128.4, 136.6, 137.3, 143.0, 146.4, 155.5 
2-(4-Nitrophenyl)-4-(1-(R)-benzyloxycarbonylaminoethyl)-1H-imidazole (6b)
The title compound was synthesized from α-bromoketone 4b (8.7 g, 29.0 mmol) following the general method. Yellowish solid, yield 3.9 g (37% 45.1, 65.3, 124.3, 125.4, 127.8, 128.4, 136.6, 137.3, 143.0, 146.4, 155.5 
2-(4-Nitrophenyl)-4-(1-(S)-benzyloxycarbonylamino-2-methylpropyl)-1H-imidazole (6c)
The title compound was synthesized from α-bromoketone 4c (9.5 g, 29.0 mmol) following the general method. Yellow-red solid, yield 1.1 g (10% 4, 19.6, 32.2+32.7, 55.4, 65.2+65.5, 116.3, 124.3, 125.3, 127.7, 127.8, 128.3, 136.6, 137.3, 142.7, 144.5, 146.3, 156 
2-(4-Nitrophenyl)-4-(1-(S)-benzyloxycarbonylamino-2-phenylethyl)-1H-imidazole (6d)
The title compound was synthesized from α-bromoketone 4d (10.9 g, 29.0 mmol) following the general method. Red solid, yield 2.1 g (16% 
2-(4-Nitrophenyl)-4-(1-(S)-benzyloxycarbonylamino-2-methylbutyl)-1H-imidazole (6f)
The title compound was synthesized from α-bromoketone 4f (9.9 g, 29.0 mmol) following the general method. Orange solid, yield 0.8 g (7% 
2-(4-Nitrophenyl)-4-(1-benzyloxycarbonyl) pyrrolidine-2-(S)-yl-1H-imidazole (6g)
The title compound was synthesized from α-bromoketone 4g (9.5 g, 29.0 mmol) following the general method. Yellow solid, yield 3.1 g (28% 6+23.5, 31.8+32.9, 46.1+46.6, 55.2+55.6, 65.4+65.7, 115.9+116.1, 124.3, 125.3, 126.9+ 127.4, 127.3+127.7, 128.1+128.4, 136.6, 137.3, 142.9, 145.3+145.9, 146.3, 153 
Biological activity
The antimycobacterial activity screening was carried out in the Laboratory for Mycobacterium diagnostics of the Institute of Public Health in Ostrava. The antimycobacterial activities of the compounds 5-6 were evaluated in vitro against Mycobacterium tuberculosis CNCTC My 331/88, M. kansasii CNCTC My 235/80, M. kansasii 6509/96 and M. avium CNCTC My 330/88. Micromethod for the determination of the minimum inhibition concentration (MIC) was used. All tested strains were obtained from the Czech National Collection of Type Cultures (CNCTC), except of M. kansasii 6509/96, which was clinically isolated. The activities of the compounds were determined in the Šula semisynthetic medium (SEVAC, Prague). The compounds were added to the medium in dimethylsulfoxide solutions. The following concentrations were used: 1000, 500, 250, 125, 62, 32, 16, 8, 4 and 2 mmol L -1 (binary dilution steps). The MIC values were determined upon incubation at 37°C for 14 and 21 days and in the case of M. kansasii 7, 14, and 21 days, respectively. The MIC values were determined as the lowest concentration of a substance in binary dilution steps performing the inhibition of the growth of Mycobacteria. Isonidazid (INH) was used as a standard.
Results and discussion
Synthesis of target compounds
The synthesis of target compounds 5 and 6 is outlined in Scheme 1. The synthesis started from commercially available nonpolar α-amino acids such as (S)-Ala (a),
, and (S)-Pro (g) and their N-protection using benzylchloroformate to afford N-Cbz protected α-amino acids in the yields of 93-97% [13] . Activation of the carboxylic acids via formation of mixed anhydride and its subsequent treatment with ethereal diazomethane solution afforded smoothly α-diazoketones 3a-g in the yields of 90-98%. These α-diazoketones easily release nitrogen if treated with hydrobromic acid (48%), yielding α-bromoketones 4a-g. Compounds 4a-g proved to be very useful 1,2-dielectrophiles and may react with a variety of nucleophiles, e.g. the reaction with 1,3-dinucleophiles such as amidines led to imidazole derivatives [15] . Thus, the condensation of either commercially available benzamidine or 4-nitrobenzamidine hydrochlorides in the system of THF/H 2 O/Na 2 CO 3 afforded target 2-phenylimidazole derivatives 5 and 6. Starting 4-nitrobenzamidine was prepared from 4-nitrobenzonitrile and its sodium methoxide-catalyzed conversion to imidoester and subsequent treatment with ammonium chloride in 59% overall yield [14] . Whereas the reaction of α-bromoketones 4a-g with benzamidine proceeded smoothly within 12 h affording the desired 2-phenylimidazole derivatives 5a-g in good yields (42-89%), the reaction with electron poor 4-nitrobenzamidine required significantly prolonged reaction times up to 72 h. However, the attained reaction yields were modest (7-37%, Table 1 ). The compound 6e (derived from (S)-Leu) was detected in the crude reaction mixture, however, its attempted isolation was always unsuccessful.
Antimycobacterial activities
The antimycobacterial activities of both series of compounds 5a-g and 6a-g were screened in vitro against M. tuberculosis, M. avium, and two strains of M. kansasii and their minimum inhibition concentrations (MIC) were compared with the MIC values of the conventional antimycobacterial agent -isoniazid (INH). kansasii strains. The structure-activity relationships indicate that the nitro substituted 2-phenylimidazoles 6a-g possess higher antimycobacterial activities than unsubstituted analogs 5a-5g. Whereas the absolute configuration of the α-amino acid side chain did not play any role on the antimycobacterial activity (compare 5a/5b or 6a/6b), the activity is mostly affected by the increasing bulkiness of the substituent R (6c-f). Thus, compound 6d (R = benzyl, R´ = NO 2 ) is the most active compound from the evaluated series of agents.
Conclusions
We have designed, synthesized, and further tested N-Cbz protected α-amino acid-derived 2-phenylimidazoles as potential antimycobacterial agents. Overall thirteen compounds with different α-amino acid side chains (a-g) and 4-nitro substitution at the appended phenyl ring were investigated. These compounds were accessible from the commercially available N-Cbz protected α-amino acids in a three step synthesis involving formation of α-diazoketones, α-bromoketones, and their subsequent condensation with amidines. The yield of the final condensation step was strongly affected by the electron behavior of the benzamidine pendant. However, target compounds 5a-g and 6a-g can be obtained in a multigram scale in this way. The anitmycobacterial activities of compounds 5 and 6 were tested in vitro against four strains. Whereas the activities against M. tuberculosis were lower than those of commercial isoniazid, the activities against M. avium and M. kansasii CNTCT exceeded the activity of INH. The main structural features affecting the antimycobacterial activities of tested compounds 5 and 6 are i) the presence of nitro group and ii) the bulkiness of the α-amino acid residue. 2-Phenylimidazole derivatives bearing nitro group and larger α-amino acid residue such as iPr, Bn or iBu (6c-f) showed to be the most effective compounds from the studied series.
